Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
The University of Texas at San Antonio Health Science Center · North Central Cancer Treatment Group
Abstract
Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).
Recurrent GBM patients with
Citation impact
- FWCI
- 26.47
- Percentile
- 100%
- References
- 33
Authors
15- EGEvanthia GalanisCorresponding
The University of Texas at San Antonio Health Science Center, North Central Cancer Treatment Group
- JCJan C. Buckner
The University of Texas at San Antonio Health Science Center, North Central Cancer Treatment Group
- MJMatthew J. Maurer
The University of Texas at San Antonio Health Science Center, North Central Cancer Treatment Group
- JIJeffrey I. Kreisberg
The University of Texas at San Antonio Health Science Center, North Central Cancer Treatment Group
- KVKarla V. Ballman
The University of Texas at San Antonio Health Science Center, North Central Cancer Treatment Group
Topics & keywords
- Temsirolimus
- Medicine
- Internal medicine
- Gastroenterology
- Toxicity
- Cmax
- Regimen
- Sirolimus
- Good health and well-being